Press Releases

News & Media

Newport Beach, California--(Newsfile Corp. - November 12, 2019) - Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announces its ongoing support of empowering women in the workplace. The company believes that empowering women drives innovation and as such, has several women in high-level positions at Vivera. Women serve as co-founders of the Company, members on Vivera's Advisory and Ambassador Board and in Executive Level Positions including the CEO of Vivera's Health and Human Service Division, Vivera's Chief Financial Officer, Vivera's Global VP of Sales and Marketing and the Company's National Clinical Director.

"Equality and inclusivity in the workplace are important," said Paul Edalat, Chairman and Founder of Vivera. "We take talent diversity and workforce inclusion seriously and make it a priority to recruit and promote women. From my years of experience, empowering women leads to innovation and creates a competitive advantage so it's not only the right thing to do - it's the smart thing to do."

Women make up nearly half of the workforce and according to AmericanProgress.org, women earn approximately 57 percent of undergraduate degrees, 59 percent of master's degrees, 48.5 percent of all law degrees and 47.5 of all medical degrees. Despite these gains, women in leadership positions remain highly unrepresented. The highest percentage of female CEOs of Fortune 500 companies reached an all-time high of just 6.4% in 2017 with less than 5% in 2018 and only two women of color CEOs in the Fortune 500. The gender gap in pay is also still an issue with the Census Bureau reporting that full-time working women in the United States earn approximately 80% of what men earn.

Women and men bring different skills and perspectives to the workplace, including different attitudes to risk and collaboration. A more diverse perspective can make companies, especially consumer focused and patient-centric companies like Vivera stronger. Previous research shows that the financial performance of firms improves with more gender-equal corporate boards. In a study by the Center for Creative Leadership, results suggest that having more women in the workplace actually makes an organization a better place to work in terms of job satisfaction, more meaningful work, and less burnout. In their research, this was true for both men and women.

"Vivera is a Company with a greater purpose of helping people," said Ms. Olivia Karpinski, Co-Founder and Director. "A major component of the Company's vision is to have a positive impact on the opioid crisis and to improve people's lives. We have a strong team of seasoned professionals who support each other because we all share the same vision. The work we do is fulfilling and having a diverse team has led to remarkable results."

Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.

In addition to its pharmaceutical and medical device products, the company has global exclusivity to license the patented and patent-pending TABMELT™ sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.

Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELT™ drug delivery format with the goal of gaining FDA approval for its products.

The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.

The securities described herein, if any, have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any of Vivera Pharmaceuticals securities in the United States. This news release may contain "forward-looking information" as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera Pharmaceuticals, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera Pharmaceuticals and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera Pharmaceuticals future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera Pharmaceuticals' expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera Pharmaceuticals, reference should be made to Vivera Pharmaceuticals continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera Pharmaceuticals CSE Listing Statement. The forward-looking information contained in this release is made as of the date of this release. Vivera Pharmaceuticals does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents of this press release.